National Journal of Maxillofacial Surgery

: 2022  |  Volume : 13  |  Issue : 1  |  Page : 5--10

Medication-related osteonecrosis of the jaw: An update

Hitesh Bansal 
 Faculty of Dentistry, Oral and Craniofacial Sciences, Guy's Hospital, London, United Kingdom

Correspondence Address:
Mr. Hitesh Bansal
Apartment 92 Metro Central Heights, 119 Newington Causeway, London SE1 6BB
United Kingdom

Antiresorptive medications, such as bisphosphonates and denosumab, are an important class of medication used to treat a wide range of diseases from osteoporosis to multiple myeloma. Unfortunately, they are also associated with a rare but devastating side effect – medication-related osteonecrosis of the jaw (MRONJ). First reported in 2003, much research has been done into the area; however, the exact pathophysiology continues to elude clinicians and researchers. What has been ascertained is that intravenous treatment, duration of treatment, and tooth extraction are major risk factors. Staging and treatment guidelines have been proposed; however, there has been no universal acceptance, and clinicians rely on various position papers. Over the next 30 years, the aging population is set to double, and with it, the prescription of antiresorptive medication and incidence of MRONJ will undoubtedly increase. In 2013, Gupta et al. published a paper on bisphosphonate-related osteonecrosis of the jaw; however, there have many changes since then. This paper aims to provide a succinct update on those changes.

How to cite this article:
Bansal H. Medication-related osteonecrosis of the jaw: An update.Natl J Maxillofac Surg 2022;13:5-10

How to cite this URL:
Bansal H. Medication-related osteonecrosis of the jaw: An update. Natl J Maxillofac Surg [serial online] 2022 [cited 2022 Dec 9 ];13:5-10
Available from:;year=2022;volume=13;issue=1;spage=5;epage=10;aulast=Bansal;type=0